Regentis Biomaterials Ltd. (RGNT) Fair Value 2026

RGNT · Orthopedic, Prosthetic & Surgical Appliances & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.7 /10

32 fundamental signals · 9 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Regentis Biomaterials Ltd. (RGNT) trades at $2.40, approximately 262% above CirclFi’s Bayesian DCF fair value of $0.66. QOC: 4.7/10. 9/13 models active.

Key Facts

Ticker
RGNT
Price
$2.40
Quality Score
4.7/10
Value Trap Risk
—/100
Models Active
9/13
Last Updated
Strength: First Chicago suggests +98.0% upside with 9% confidence
Risk: Below-average Quality Score of 4.7/10 signals weak fundamentals

Is Regentis Biomaterials Ltd. (RGNT) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Regentis Biomaterials Ltd. (RGNT) appears overvalued as of : the median of 9 independent fair value estimates is $1.17, 51.2% below the current price of $2.40. Estimates range from $0.06 to $10.97. RGNT scores 4.7/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Regentis Biomaterials Ltd. Stock in 2026? →

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($2.40)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.66 -72.4%
CUCE Ensemble
Low Conviction
 $3.90 +62.1%
First Chicago
Low Conviction
 $4.76 +98.0%
RCMH-DCF
Medium Conviction
 $1.00 -58.4%

Unlock the Full Matrix

Access 5 additional models including ML-RIV, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is Regentis Biomaterials Ltd. (RGNT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Regentis Biomaterials Ltd. at its current price of $2.41. The composite intrinsic value is estimated at $2.82 (+17.4% average return), with 5 models flagging overvaluation risk. The most optimistic model, FTNN, places fair value at $10.97 (+356.0%), while Sentiment SOTP — the most conservative — estimates $0.06 (-97.6%). This +453.6% gap reflects genuine analytical uncertainty about Regentis Biomaterials Ltd.'s intrinsic worth.

What Do the Models Say About RGNT?

9 of 13 models are currently active for RGNT. Of these, 4 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates RGNT's intrinsic value at $0.66, implying -72.4% downside from the current price. See which stocks rank higher →

How Does RGNT Rank in Orthopedic, Prosthetic & Surgical Appliances & Supplies?

Among 25 Orthopedic, Prosthetic & Surgical Appliances & Supplies stocks, RGNT ranks #20 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.

Regentis Biomaterials Ltd. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is RGNT a Value Trap?

The Value Trap algorithm is not active for RGNT. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Regentis Biomaterials Ltd.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Regentis Biomaterials Ltd.'s fundamental quality profile registers 4.7/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +453.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RGNT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RGNT's 9 active models, average confidence is 15%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Regentis Biomaterials Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Orthopedic, Prosthetic & Surgical Appliances & Supplies Stocks Should You Also Analyze?

8 related Orthopedic, Prosthetic & Surgical Appliances & Supplies stocks with 13-model coverage

STESTERIS plc (Ireland)QOC 9.7ISRGIntuitive Surgical, Inc.QOC 9.5EWEdwards Lifesciences CorporatioQOC 8.9MSAMSA Safety IncorporatedQOC 8.8CDRECadre Holdings, Inc.QOC 8.3SNNSmith & Nephew SNATS, Inc.QOC 8.2SPAISafe Pro Group Inc.QOC 7.1ESTAEstablishment Labs Holdings IncQOC 7.1

Read investment analysis: STE · ISRG · EW · MSA · CDRE

Frequently Asked Questions About Regentis Biomaterials Ltd.

What is Regentis Biomaterials Ltd.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Regentis Biomaterials Ltd. (RGNT) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.66. The Quality of Company score is 4.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RGNT overvalued or undervalued right now?

At $2.40, 4 of 9 active models suggest RGNT may be undervalued, while 5 indicate potential overvaluation. The median of all 9 fair value estimates is $1.17, 51.2% below the current price of $2.40 — a consensus view that RGNT is overvalued. The assessment depends on which methodology best fits Regentis Biomaterials Ltd.'s business model in Orthopedic, Prosthetic & Surgical Appliances & Supplies.

What does a Quality of Company score of 4.7 mean for RGNT?

Regentis Biomaterials Ltd.'s QOC of 4.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RGNT?

CirclFi analyzes RGNT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is RGNT a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for RGNT at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Regentis Biomaterials Ltd. (RGNT) has a median fair value of $1.17 — 51.2% below the current price of $2.40 — as of 2026-07-15.” Source: circlfi.com/stock/RGNT/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on RGNT.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access